Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Correct, low volume downward pressure, no communication.
Are you saying this isn't a legitimate company, but a pump and dump?
Tim, look at that, bid and ask below current price. No volume... No one posting on the board... Are the stars aligning?
June , 2020
Dear Stockholder:
You are cordially invited to attend a special meeting of stockholders of CytoDyn Inc. (the “Company”) to be held at 9:30 a.m., Pacific Time, on Wednesday, July 22, 2020, at the Hilton Vancouver Washington, 301 W. 6th Street, Vancouver, Washington 98660.
The matters to be presented for action at the meeting are a proposal to increase the total number of authorized shares of common stock from 700,000,000 to 800,000,000 shares, as further described in the enclosed proxy statement, and a proposal to approve the adjournment of the special meeting to solicit additional proxies if there are insufficient proxies at the special meeting to approve the foregoing proposal.
We are excited about the future of our company and look forward to answering questions from our stockholders at our special meeting. Whether or not you can attend, it is important that your shares are represented and voted. Please sign, date, and return your proxy, or submit your proxy by telephone or Internet as instructed on the enclosed proxy card.
Sincerely,
Nader Z. Pourhassan, Ph.D.
President and Chief Executive Officer
Think about it Tim. Do you think that you've stumbled on the gold stock of the year, and no one else has? Company had been around for more than a decade with nothing to show. There is a reason that no one is talking about this or buying it.
Cause everyone knows it's a scam
Pretty good read, wish we were mentioned though...
https://www.fool.com/investing/2020/05/17/why-gileads-remdesivir-might-not-be-the-mega-money.aspx
2019 top pharmaceutical acquisitions
https://www.europeanpharmaceuticalreview.com/article/111051/the-biggest-pharma-merger-and-acquisition-deals-of-2019/
Late Friday PR
https://www.cytodyn.com/newsroom/press-releases/detail/434/cytodyn-to-hold-conference-call-to-provide-updates-on
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS
Download as PDFMay 22, 2020 8:49pm EDT
VANCOUVER, Washington, May 22, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Jacob Lalezari, M.D., Chief Science Officer, will host an investment community conference call on Tuesday, May 26, 2020 to provide a comprehensive update on several recent clinical and regulatory developments.
Management will dedicate approximately 30 minutes to address questions from analysts and investors.
Date: Tuesday, May 26, 2020
Time: 1:00 p.m. PT / 4:00 p.m. ET
Dial-In: 877-407-2986 US / 201-378-4916 International
A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software. The webcast can also be accessed via the following link:
https://78449.themediaframe.com/dataconf/productusers/cydy/mediaframe/38441/indexl.html
A replay of the conference call will be available until June 26, 2020. To access the replay, interested parties may dial 877-660-6853 (US) / 201-612-7415 (international) and enter conference identification number 13702767.
Wow, hopefully that makes the rounds.
I was in meetings during the call. Was there anything mentioned on the delay of the peer review release?
Looking good! Eye roll
Thank you for the link, it's great news. Just keep providing links and they nay Sayers can't touch it. Facts and science!
Please stop making up numbers. It's just as bad as the shorts. Facts and science is what will move this along. If we have a $4 target fantastic, provide a link
Can someone please provide me that article that summarized ADAM FEUERSTEIN's short attacks?
Almost seems legit... Eye roll
He sure does mention the company and Nadar in his hit pieces. Look at the title,
"CytoDyn says lead HIV drug was not filed for FDA approval, as previously claimed"
"On Thursday night, Pourhassan found himself with a new problem: An admission that CytoDyn misled investors"
None of that happened, he straight up lied, and that is why the SEC complaints were filed. I hope the company goes after him/ statnews for libel.
There are NO lawsuits,
Currently "investigating"
It's a bogus witch hunt to smear the name of the company. The company DID submit the BLA on April 27th as stated in the PR, therefore no fraud was committed.
Exactly, there is no interest in this company. No one is holding tight...more like no one is buying
If the number is $1000 per dose...2-3 doses are required which would reduce patients needed. There has been over 4m to date, what will happen throughout the rest of the year is unknown. Wave 2 in the fall may be worse.
Nice read on Whistle blower Rick Bright
https://www.cbsnews.com/news/rick-bright-vaccine-expert-removed-trump-administration-60-minutes-2020-05-08/
Stat news and Adam F needs to be sued for slander. He directly stated that the company did not file the BLA which was a lie. They filed and the FDA requested more data. Which IMO was a good thing, the FDA already went through our submission, especially with everything that is going on with Covid.
Most likely they were tipped off by someone, and are looking to start a class action lawsuit, they are just as bad as Adam F and his hit pieces.
Based on what? Are you just making numbers up to pump?
I know what actually happened. I was saying, to the people that were saying he sold to get out. IF he was going to do that, he had the opportunity to make more money.
The way I look at it is, if NP was going to sell why do it at these levels? He could make a deal and sell the company cheap and double/triple what he would've had if he sold now. I'm sure these is a company out there that would've paid $6/share to own the rights to leronlimab.
NEWS
VANCOUVER, Washington, May 04, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the Company is expecting enrollment completion for its 75 patient, Phase 2 double blinded, placebo controlled, randomized study by the end of this month.
CytoDyn has submitted a request to the FDA to grant expanded access, also known as “compassionate use,” to make leronlimab available for patients not eligible for participation in two ongoing clinical trials for coronavirus infections. Many severe and critically-ill patients, who have received off-label immunomodulatory treatments for COVID-19, are excluded from participation in the Company’s Phase 2b/3 clinical trial and could potentially benefit from access to leronlimab under a compassionate use program.
There are 49 COVID-19 patients who have enrolled for treatment with leronlimab through eIND. Four out of 11 critically ill patients with a multitude of pre-existing conditions survived after treatment, and of the next 38 patients, many were extubated, improved, or were discharged.
Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, “We are very excited about the continuing positive responses from eIND patients following their treatment with leronlimab. We are equally excited about the prospects for patients should the FDA grant access to leronlimab under the compassionate use program. During this past Saturday, we had to overcome many obstacles for two patients who desperately wanted leronlimab. One patient was in the same hospital that enrolled the first 11 patients and the second was a VIP patient in Los Angeles. Under the compassionate use program, we could avoid and quickly overcome this type of stress and turmoil which was very difficult for the patients, their families, the physicians, and CytoDyn. The daughter of a patient who was on a machine used for severe heart and lung failure contacted us directly and expressed her immense gratitude believing leronlimab saved her mother’s life. These are amazing times for us at CytoDyn; with the opportunity to wake up every day with the potential of saving somebody’s life. For sure, I could never have imagined such an incredible honor.”
Per Chump
Happy Sat to all- I have read a lot of opinions/noise on NP's recent filing here and there. Hopefully this will put it to rest for some.
I had my broker contact NP directly about it.
Summing it up...CYDY had a deadline to meet with Samsung. CYDY and Samsung have an extremely good relationship. NP exercised his warrants/options (cashless to him) to bring CYDY current. NON DILUTIVE TO SHAREHOLDERS.
This will allow CYDY and Samsung to move forward with production that is at it's highest demand ever.
Here's a simple scenario?- You order 50 of a product and it's time to pay but you have new orders of 500,000 and climbing every day. Well pay for that 50 on time.. and quickly... then the relationship builds as your order books rise.
What is NP's email? I will email him, and get clarity for this. IMO What has transpired is a good thing.
I don't believe any shares were sold. It looks like warrants were exercised. I take that as a positive step in the uplisting direction. Per the call yesterday NP stated that if people exercised their options, then we could uplist without diluting.
That's how I read it. And I take it as a positive. As mentioned on the Wall st call. People need to exercise warrants so we can uplist without diluting. NP took the first step.
Did you specifically ask about the Form 144? Either way I don't see anything bad happening.
If he truly didn't do that, then we have another issue as that was submitted to the SEC.
Either way what it looks like is he exercised options. On the wall st call he mentioned if shareholders exercised option then we could uplist. So maybe it exercised some of his options to show good faith and get the ball rolling?
Unfortunately I don't think it is fake. I opened the link, downloaded the zip, there are many files in the zip, towards the bottom is one for Nadar, and Cytodyn.
Table 1 Securities to be sold
Under nature of acquisition it states; stock option exercise
Number of shares; 4,504,327
under nature of acquisition it states; award grant
number of shares; 317,417
nature of payment; cashless exercise grant
What are you talking about? There is a presentation on Wall Street reporters today, at 12:30est